Use of Insulin Glargine to Treat Diabetic Ketoacidosis

Completed · Not applicable · Has a placebo group

Conditions studied: Diabetic Ketoacidosis

In brief

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.

Key facts

Study ID

NCT00179127

Run by

Vanderbilt University Medical Center

People needed

75

Starts

2004-08-01

Expected to finish

2012-09-01

Last updated by the study team

2018-07-16

Who can join

Age: 6 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with:
• Established history of insulin dependent diabetes
• AND:
• Chief c/o hyperglycemia or vomiting
• Venous pH < 7.24
• Serum Bicarbonate < 18
• Blood glucose > 150
• Urinary Ketones

You may not qualify if…

• Age < 6y.o.
• New onset diabetes
• Received IV insulin bolus prior to arrival to VCH Emergency Room (ER)
• Venous pH > 7.24
• Serum Bicarbonate > 18
• Pregnancy
• Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit

Where it is running

• Vanderbilt University Monroe Carell Children's Hospital — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.